	Myelodysplastic syndromes
Treatment guidelines
MDS
Lenalidomide
	lenalidomide
common
patients
MDS
therapy
adverse events
treatment
Table
expert panel
response
additional cytogenetic abnormalities
clinical trials
risk
chromosomal abnormalities
neutropenia
transfusion-dependent
bone marrow blast count
continuous
VTE
panel
clinical data
NHAEs
grade
drug
intermediate1
order
abnormality
dose
disease
data
time
recommendations

